Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer

Autor: John H. Maduro, Elisabeth Pras, de Elisabeth G. E. Vries, Phb Willemse
Rok vydání: 2003
Předmět:
medicine.medical_specialty
cervical cancer
Nausea
medicine.medical_treatment
Urogenital System
Uterine Cervical Neoplasms
Antineoplastic Agents
GYNECOLOGIC-ONCOLOGY-GROUP
chemotherapy
Gastroenterology
Fractures
Bone
QUALITY-OF-LIFE
Internal medicine
medicine
Humans
Radiology
Nuclear Medicine and imaging
Vascular Diseases
Cervical cancer
Chemotherapy
Radiotherapy
business.industry
Genitourinary system
FRACTURES FOLLOWING IRRADIATION
UTERINE CERVIX
Neoplasms
Second Primary
Radiotherapy Dosage
General Medicine
medicine.disease
Combined Modality Therapy
Acute toxicity
FRANCO-ITALIAN GLOSSARY
Surgery
Radiation therapy
side effects
Oncology
Chemotherapy
Adjuvant
ATHEROSCLEROTIC OCCLUSIVE DISEASE
CISPLATIN-BASED CHEMOTHERAPY
Toxicity
Vomiting
Quality of Life
Female
SQUAMOUS-CELL CARCINOMA
NONSEMINOMATOUS TESTICULAR CANCER
medicine.symptom
business
Digestive System
PELVIC RADIATION-THERAPY
Zdroj: Cancer treatment reviews. 29(6)
ISSN: 0305-7372
Popis: Randomised studies in locally advanced cervical cancer patients showed that cisplatin should be given concurrently with radiotherapy, because of a better long-term survival compared to radiotherapy alone. This increases the relevance of treatment related toxicity. This review summarises the acute and long-term toxicity of radiotherapy given with or without chemotherapy for cervical cancer. Acute toxicity (all grades) of radiotherapy is reported in 61% of the patients in the rectosigmoid, in 27% as urological, in 27% as skin and in 20% as gynaecological toxicity. Moderate and severe morbidity consists of 5% to 7% gastrointestinal and 1% to 4% genitourinary toxicity. Adding chemotherapy to radiotherapy increases acute haematological toxicity to 5% to 37% of the patients and nausea and vomiting in 12% to 14%. Late effects of radiotherapy include gastrointestinal, urological, female reproductive tract, skeletal and vascular toxicity, secondary malignancies and quality of life issues. For at least 20 years after treatment, new side effects may develop. Gastrointestinal toxicity usually occurs in the first 2 years after treatment in about 10% of the patients. The incidence of moderate and severe urological toxicity can increase up to 10% and rises over time. Gynaecological toxicity usually occurs shortly after treatment while skeletal and vascular toxicity can occur years to decades later. Thus far, no increase in late toxicity has been observed after the addition of cisplatin to radiotherapy. Finally, methods to prevent or decrease late toxicity and therapeutical options are discussed. However, most randomised studies still have a limited follow-up period. (C) 2003 Elsevier Ltd. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: